• Renewable energy is the future of energy
• Vanadium batteries are uniquely suited to the task of rolling out renewable energy on a larger scale
• Perhaps one of the most compelling advantages of vanadium flow batteries is their cost

The debate is over, according to a recent StorEn Technologies blog: renewable energy is the future of energy (https://ibn.fm/IlQCs). The only discussion left, according to the company, is identifying the best path to get there. “At StorEn Technologies, we believe that vanadium flow batteries are the key to making sustainable energy sources like solar power more widely accessible,” states the blog, which outlines why the benefits of vanadium flow batteries make them “uniquely suited to the task of rolling out renewable energy on a larger scale and helping more people and businesses achieve independence from the electrical grid.” According to StorEn, vanadium flow batteries offer superior discharge capacity and a long lifespan. The company says the batteries have an expected lifespan of 25 years or more — with no degradation of performance even as a battery nears the end of its life. The batteries also provide sustainable energy storage. The blog notes that unlike lithium batteries, vanadium flow batteries will always discharge fully at 100%. “There is no decaying or losing of capacity over time. In other words, 100% of the initial battery capacity is available through a vanadium flow battery’s entire lifetime, making it easier to match daily demands with generation.” In addition, vanadium batteries are also safer, low maintenance and more versatile. “Lithium batteries present several significant disadvantages when it comes to safety; vanadium flow batteries have none of these,” the blog explains. “Because their electrolyte is water based, vanadium flow batteries are nonflammable and also nonexplosive, giving vanadium flow batteries the highest level of safety when compared to other battery technologies.” StorEn vanadium flow batteries offer hassle-free maintenance as well. The StorEn Battery Management System sends a notification when service is required, eliminating the need for scheduled maintenance. And the batteries can be used both inside and outside in a wide range of temperatures. “While vanadium flow batteries are most often used for grid storage at present, future innovations and cost reductions once economies of scale kick in will make this technology more commonplace,” the blog states. On top of these significant benefits, perhaps one of the most compelling advantages of vanadium flow batteries is their cost. “Thanks to their longer lifespan and because vanadium flow batteries do not lose capacity over time and continue to discharge fully until replacement, they are a cost-effective choice when compared to lithium with the lowest cost/cycle possible today,” the blog notes. “Lithium batteries also have higher disposal costs, while vanadium electrolyte retains its value at end-of-life. StorEn has developed evolutionary vanadium flow batteries. Incubated at the Clean Energy Business Incubator Program (“CEBIP”) within Stony Brook University in New York, the company is building upon the strengths of vanadium flow batteries to revolutionize the world of residential and industrial energy storage. The company is off StorEn is in the process of a RegA offering with four different investment tiers; each tier offers a different discount and reward. (Click here for more information.) With a proprietary product that answers the call for long-lasting, 100% recyclable, safe and affordable energy storage, StorEn and its disruptive, patent-pending, all-vanadium flow battery technology for energy storage holds real promise in a growing market. For more information, visit the company’s website at www.StorEn.tech. NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies are available in the company’s newsroom at https://ibn.fm/StorEn

• A recent analysis reports that the cannabis sector is projected to add approximately $92 billion to the general U.S. economy this year
• From jobs to tax revenue to commercial real estate, the marijuana industry has a growing impact on broader U.S. economy
• Hero Technologies is planning expansion in cultivation and dispensary operations

Companies operating in the cannabis space in the United States sometimes have to deal with negative stereotypes and news, but this week, cannabis headlines focused on the positive. A recent MJBizFactbook analysis reports that the cannabis sector is projected to add approximately $92 billion to the general U.S. economy this year (https://ibn.fm/RF9pN). Hero Technologies (OTC: HENC), a cannabis company focused on growing into a multistate, vertically integrated entity with strong cultivation and dispensary assets, is in a position to contribute to this economic benefit. “From jobs to tax revenue to commercial real estate, the marijuana industry has a large — and growing — impact on the broader economy in the United States,” reported an MJBizDaily article. “The total U.S. economic impact from marijuana sales in 2021 is expected to reach $92 billion – up more than 30% from last year – and upwards of $160 billion in 2025, according to analysis from the newly published MJBizFactbook.” The article notes that the numbers are a best guess because the marijuana industry’s structure is somewhat unique because it encompasses agricultural, manufacturing and retail activity. The projected impact may be even greater than the dollar-amount indicates, according to the article, which notes that in calculating these particular numbers, analysts believe that each dollar that a patient or recreational user of marijuana spends at a retail outlet translates into an extra $2.5 injected into the local economy. “Those additional dollars added to local economies arise because employees of cannabis firms spend on food, transportation, housing, entertainment as well as other necessities of life. Furthermore, buyers of cannabis products also pay local and state taxes or fees,” the article stated. “This increases the impact of their purchase upon the economy since those tax dollars go to maintaining schools, building infrastructure and meeting other expenses at the state or even federal level. This is where the broader U.S. economy benefits, according to the MJBizFactbook team.” As Hero Technologies Inc. focuses on growth and expansion, the company could be a contributor to this boon to the country’s economy. HENC’s growing portfolio includes a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased efficiencies. Hero Technologies is also planning expansion in cultivation and dispensary operations into both Colorado, through its wholly owned subsidiary Mile High Green LLC, and Massachusetts, through wholly owned subsidiary MassCannabis LLC. In addition, Hero Technologies owns and operates two hemp websites: HighlyRelaxing.com under Highly Relaxing LLC and VeteranHempCo.com. HENC is working toward a vertically integrated business model. The company’s strategic business plan includes cannabis genetic engineering, space for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Company taking active steps to eliminate debt, ramp up growth, open access to shares
• ISWH signs agreement with GPL Ventures to eliminate over $2.4 million in convertible promissory notes
• Company has started mining and expects to reach larger objectives laid out for mining progress and results in 2021

ISW Holdings (OTC: ISWH), a global brand management holdings company, has released a shareholder update on the status of its convertible debt resolution process, mining operations and upcoming audit results (https://ibn.fm/67Wqm). The company currently has commercial operations in telehealth and renewable energy cryptocurrency mining. “We continue to work hard every day to drive shareholder value through a combination of growth and transparency,” said ISW Holdings president and chair Alonzo Pierce. “We are eliminating structural financial risk and ramping tangible growth, all while taking active steps to open up access to our shares to a widening audience. Looking ahead, we have a number of exciting steps in front of us that stand to directly expand our operational potential. It’s going to be an exciting second half of the year.” In the update, the company reviewed its position on convertible debt, crypto mining and uplisting. “In early April 2021, the company announced that it had signed an agreement with GPL Ventures (‘GPL’) to eliminate over $2.4 million in convertible promissory notes,” the update reported. “That agreement covered all convertible debt held by GPL and represented more than 92% of the Company’s outstanding convertible debt obligations. Now, the company further announces that the settlement agreement, and all of its stipulations, has been satisfied, with its payment wired to GPL. All related notes have been stamped ‘paid.’” In addition, the company noted that it has begun crypto mining. “Management expects to catch up to the larger objectives laid out for mining progress and results in 2021, with its projects in Pennsylvania and Georgia getting up and running at reputable hash rates, which should drive strong topline growth for ISW Holdings this year,” the report noted. “The company continues to target a carbon-neutral mining paradigm.” Finally, ISWH noted that it plans to complete an audit of its 2020 performance over the near term. “Once that is complete, management will file Form 10 with the U. S. Securities and Exchange Commission. Management believes the filing of Form 10, and filing future events with the SEC, will help strengthen the case for further uplisting of shares following its establishment on the OTCQB tier.” ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands and anticipated marketplace needs. The company meets those needs through a variety of strategic innovative processes. ISW Holdings is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

Date: July 28-30, 2021 ONLINE LIVESTREAM On July 28-30, 2021, medical officers and healthcare professionals are invited to attend DGE’s 4th Digital & Innovation For Medical Affairs Summit to learn and upskill with the progressive technologies and novel policies of the digital era. This online live streaming event is organized by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The COVID pandemic has paved way for enormous changes that both patients and HCPS are adapting to. The need for relevant, speedy, and precise scientific information is now greater than ever. The need of the hour is the complete transformation of medical affairs departments by incorporating new policies and patient-centricity demonstrating value to both internal and external stakeholders in a digital era. With this online conference, medical professionals can join our growing community of interactive participants who can learn the nitty-gritty of the digital revolution. Throughout the conference, industry leaders, health providers, and policymakers will come together to explore the opportunities around innovation, better accessibility and efficiency, and the expedition of healthcare into the digital format that the pandemic has catalysed. They will further discuss and offer their insights into the challenges faced by the medical professionals while adapting to novel technologies and the vulnerabilities posed by the COVID situation. The top reasons to attend:

• Best data literacy that gives an edge over the competition
• Leverage the novel digital strategies for optimum patient information and care
• Stay updated on new trends and technologies, and learn how to stay away from fads
• Get access to an interactive community with innovative ideas
• Meet industry stalwarts, all at one interactive platform

The event will feature two eminent spotlight speakers, Michael Kahn, Medical Affairs Operations Leader, Spark Therapeutics and Loreen Brown, Global Head, Patient Support Solutions, Medocity. Several other industry leader and speakers will share their insights and keynotes so that health providers and healthcare professionals can keep up with the acceleration of digital transformation. The COVID scenario has compelled pharma companies to change their working system and immediately transform to digital processing. Attendees will understand and explore the impact and the behavioural changes that have taken effect due to the digital transformation. This interactive session offers lessons on the incorporation of AI, and digital tools into the life science industry. For more details, please visit https://ibn.fm/Q53NY

• FingerMotion (FNGR) a rapidly evolving tech company serving markets in China, announced its financial results for the period Q1 2022
• The company generated $6.00 million in revenue, representing the fourth consecutive quarter of record revenue
• The Telecommunications Products & Services (mobile recharge platform) and the SMS & MMS texting service sectors continued to show strong growth

FingerMotion (OTCQX: FNGR) is a rapidly evolving tech company focused on its core competencies of mobile payment and recharge platform serving markets in China. The company announced its financial results for the period Q1 2022. Sectors that continued to show an upward growth graph are the telecommunications Products & Services (mobile recharge platform) and the SMS & MMS texting service (https://ibn.fm/s84J8). Here is a Financial Summary for the first quarter ended May 31, 2022:

• FingerMotion stood with $789,752 in cash, a working capital surplus of $2,352,502 and a positive shareholders equity of $1,455,643, on May 31, 2021;
• The company generated a revenue of $6.00 million (includes SMS & MMS, Telecommunications Products & Services and Big Data businesses);
• The SMS & MMS businesses recorded a growth in revenue of $1.81 million or 77% compared to Q1 2021;
• The Telecommunications Products & Services businesses recorded a revenue of $1.34 million or 341% compared to Q1 2021;
• Revenues of $98,715 or 198% in Quarter over Quarter (Q4 2021 over Q1 2022) growth in Big Data;
• The quarterly cost of revenue was recorded at $5.38 million which was an increase of $2.93 million or 120% compared to Q1 2021;
• A quarterly loss of $909,506 was reported, which was an increase of $0.33 million or 57% compared to Q1 2021;
• Basic and Diluted loss per share of $0.02;
• The company’s total assets were $8.61 million, Total Current Liabilities were $6.05 million and Total Liabilities were $7.16 million;
• 38,995,160 common shares were issued and outstanding as of May 31, 2021.

Martin Shen, the CEO of FingerMotion said that the first quarter generated $6.00 million in revenue and represented the fourth consecutive quarter of record revenue. If the surge continued, the company revenues may exceed US$24 million for FYE 2022. He further stated that it was the second consecutive quarter of Big Data revenues and they expected it to eventually outpace their other existing revenue streams. With offices in Hong Kong, Shanghai, and New York, FingerMotion is developing additional value-added technologies to expand its user base in China and other regional markets. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Ideanomics’s EV market is expected to grow exponentially, driven by growing public awareness/acceptance and the U.S. administration’s support
• The company plans its expansion moves across three strong EV pillars: vehicles, charging, and energy
• IDEX acquisition of California-based Solectrac reflects the company’s approach to an electric tractor revolution

In 2020, the number of global electric vehicles reached the 10 million mark, with battery electric vehicles (“EVs”) being the main force behind the expansion. The governments of many countries provided fiscal incentives that have acted as a catalyst for the new registration of electric cars (https://ibn.fm/zu2U7). Ideanomics (NASDAQ: IDEX), is a global company focused on revenue-based opportunities in the EV and fintech arenas, geared to leverage the boom in the global EV market. With its three strong pillars of EV (vehicles, charging, and energy) IDEX is shaping the future of energy-driven commercial fleets through its two divisions, Ideanomics Mobility and Ideanomics Capital, focused on cost reduction and environmental sustainability. The company’s businesses operations committed to sustainability and innovations include: 1. US Hybrid Powering fleets in the private and public sectors in the US and other countries, US Hybrid specializes in the design and manufacturing of zero emission powertrain components for electric, hybrid, and fuel cell medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty vehicles throughout the world. 2. WAVE With revenues crossing $7 million in 2020, Wave powers the largest electric mass transit bus fleet in the U.S, at the Antelope Valley Transportation Authority north of Los Angeles with its wireless inductive charging pads 3. Solectrac Ideanomic’s acquisition of this California-based facility reflects the company’s visionary approach towards the electric tractor revolution. This is a pioneering move benefitting farmers and crops, as EV solutions are still unheard of in this segment, while also grabbing a growing slice of agricultural market revenue. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs
• The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program
• Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company
• Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the first four months of this year alone

Bio-pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has spent months building up to the launch of several Phase 2a clinical trials for treating select neurological disorders. On July 29, investors will get the opportunity to ask company officers questions about upcoming initiatives in a Q&A that will be part of Tryp’s Fiscal Q3 Investor Day. “I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida,” Tryp Chairman and CEO Greg McKee stated in a news release about the event (https://ibn.fm/W8nTm). “The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders.” Tryp’s synthetic psilocybin formulation TRP-8802 is its lead drug candidate and is being developed as a potential treatment for fibromyalgia as well as eating disorders such as binge eating and hypothalamic obesity. Both disorders are targets for Tryp’s Psilocybin-for-Neuropsychiatric Disorders program (“PFN”) that prioritizes maladies with unmet needs based on limitations within the central nervous system Tryp is also developing TRP-8803 as another psilocybin-based drug candidate with a proprietary formulation and method of delivery to improve the patient experience. The Investor Day event will feature a presentation by Tryp’s management team on the PFN program and a discussion on the company’s upcoming milestones. For those who can’t attend the livestream of the event, a replay will be available for 30 days afterward on Tryp’s website. Venture capital investment in the psychedelics sector since 2017 has risen explosively from $1 million to $329 million during the first four months of 2021 alone (https://ibn.fm/p21zW). American psychiatrists as a group have overwhelmingly supported efforts to further use into the use of classic hallucinogens in the treatment of psychiatric disorders, which could have a trickle-down effect for neuropsychiatric issues (https://ibn.fm/DDxec) and efforts by companies like Tryp to attract funding capital. Because the Food and Drug Administration (“FDA”) remains the focal point for assessing the potential for substance abuse and possible adverse events, the establishment of rigorous clinical trials with population sizes and conditions that mirror real-world variables is imperative to advancing novel treatment candidates that may form solutions to heretofore unmet needs (https://ibn.fm/0mzFK). For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• 2021 Sequire Blockchain Conference presentations now available on demand
• Conference featured over 15 established and emerging companies across blockchain, cryptocurrency spaces
• Keynote speakers included Brock Pierce, Maja Vujinovic, Saum Noursalehi, George Stella, Brittany Kaiser

SRAX (NASDAQ: SRAX), a leading financial technology company that helps public companies unlock the power of data through its Sequire SaaS platform, recently hosted the 2021 Sequire Blockchain Conference (https://ibn.fm/fTW6e), featuring over 15 leading blockchain and cryptocurrency-focused companies along with a slew of industry experts, including Brock Pierce, Maja Vujinovic, Saum Noursalehi, George Stella and Brittany Kaiser. Brock Pierce is a prominent entrepreneur, philanthropist, blockchain pioneer, and 2020 US presidential candidate. Among his many contributions to the blockchain industry was a key role in the development of the first major virtual goods and online gaming marketplace, in addition to the creation of the first series of Initial Coin Offerings (“ICOs”) as a way for emerging blockchain companies to raise capital and increase their public profile. Also featured at the conference was General Electric CIO Maja Vujinovic, who spearheaded the integration of blockchain and AI across a variety of businesses. Joining Vujinovic was Saum Noursalehi, CEO of tZERO – a global leader in developing and commercializing blockchain-based financial technology. BIGtoken Co-Founder and President George Stella brought his digital marketing and data analytics expertise to the conference, in addition to Brittany Kaiser – a best-selling author and globally renowned expert in data protection, blockchain technology, and legislative reform. The conference was hosted on SRAX’s Sequire platform, which serves a growing community of over five million active investors and shareholders across 183 publicly listed corporate subscribers. Since its creation in 2019, Sequire has emerged as a prominent news, educational and networking portal trusted by investors focused on the rapidly growing micro-cap space. “We are excited to kick off our conference series and to provide our Sequire clients a platform to reach a large audience of both retail and institutional investors,” said SRAX CEO and Founder Christopher Miglino (https://ibn.fm/eQFc1). “Community is a very important part of Sequire, and both virtual and in-person events are an integral part of the investor community we are building.” Sequire’s conference series aims to educate investors on growing trends in the microcap space in addition to helping them identify emerging business opportunities. The Sequire Cannabis Conference kicked off the 2021 conference series last April (https://ibn.fm/9MoGQ) and was followed by the highly successful 11th Annual LD Micro Invitational in June (https://ibn.fm/BoVMc). SRAX is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its investor intelligence and communications platform. Available as a SaaS, Sequire helps public companies leverage the power of analytics through unique tools that allow them to track their investors’ behaviors and trends and use those insights to engage current and potential investors across numerous marketing channels. To view replays of the 2021 Sequire Blockchain Conference visit https://blockchain21.mysequire.com. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

5th August 2021 Pricing-Free The Decentralized Finance (“DeFi”) Industry offers a vast set of opportunities and has its set of challenges, with market finance volatility and risks increasing accordingly. The DeFi Conference 2021 is being held on 5th August 2021. This one-day free online event is a great learning and informative platform for businesses, academics, investors, and entrepreneurs to better understand the decentralized finance industry and explore the opportunities that this space offers. The DeFi Conference 2021 is organized by Bitcoin Events, a pioneer events company that hosts world-class bitcoin and blockchain conferences in Africa. The event will bring forth an unparalleled team of DeFi industry leaders and change-makers to share their experiences about how they are shaping the next era of global finance. Why should You attend the DeFi Conference 2021? 

• Connect and engage with 35+ World-Class Speakers and dynamic personas of the DeFi space as they speak about the disruptive products, services, and platforms of the DeFi Industry that they have built over the years, and the challenges surrounding these products.
• The event will showcase 2 tracks with one dedicated to DeFi and the other one to NFTs. These tracks will feature interesting topics on innovative DeFi ideas and the latest developments in the decentralized finance space.
• This conference offers a powerful medium to connect and learn from the reputed industry personnel across a spectrum of industries like insurance, finance, trading, investments, and so on.

This high-impact innovative event will feature two tracks, one about DeFi and the other about NFTs. Attendees can engage with influential DeFi industry leaders as they cover topics on financial inclusion, open finance, and the challenges in compliance, security, adoption, and regulation. New businesses and startups can gain insights from the experience of the industry veterans to develop strategies for their businesses and successful DeFi implementation. The DeFi Industry offers a huge palette of opportunities that industries, corporates, entrepreneurs, and capitalists can leverage. This conference is a viable learning platform for these sectors to gather in-depth financial information regarding the Decentralized finance industry and apply it to their business. Exhibitors will showcase their latest blockchain and cryptocurrency solutions and get a chance to interact with the attendees and establish healthy networking. In this event, like-minded individuals connect and learn about some of the most interesting blockchain use cases from a range of leading industries, international experts, startups in the Blockchain arena. For more information regarding the details of the event, please visit http://bitcoinevents.co.za/defi-conference-2021/.

• CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments
• Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway
• CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the last couple of months, demonstrating the company’s operational, financial, and strategic strengths and continuously de-risking its lead candidate Berubicin clinical program. According to a company press release providing critical operational updates, the company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (“GBM”). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021 (https://ibn.fm/57nx3). GBM is an aggressive type of brain cancer that is often difficult to treat. Most treatments only slow the progression of cancer and reduce the symptoms. Berubicin is a novel therapy for GBM and the first anthracycline to cross the blood-brain barrier and kill cancerous tumor cells in humans. The Phase 1 safety trial for Berubicin was conducted by another company 14 years ago. Since then, one patient has lived cancer-free, with two others seeing a reduction in tumor size by up to 80%. With the serious unmet medical need for new GBM treatments, CNS Pharmaceuticals applied for and was granted FDA Fast Track Designation for Berubicin. The designation will enable more frequent interactions between the FDA and the company, expediting the development and review process for Berubicin. According to CNS Pharmaceuticals CEO John Climaco, receiving Fast Track Designation is a major achievement for the advancement of Berubicin for the treatment of the most aggressive, deadly and treatment-resistant type of brain cancer (https://ibn.fm/ObyTP). “Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,” he explained. In addition to the success of Fast Track designation and commencing enrollment in the clinical trial, CNS Pharmaceuticals has secured an additional $4.7 million in gross proceeds from the Company’s ATM facility at an average price of $2.32. These proceeds help fund the ongoing clinical programs and have extended the company’s cash runway to Q2 2022. These developments are the latest of multiple achievements the company has reported since its original IPO in November 2019. These achievements include:

• Obtaining orphan drug designation for Berubicin
• Receiving approval of the Investigational New Drug (“IND”) application
• Designing a clinical trial that may support an accelerated pathway to registration
• Manufacturing a clinical supply of Berubicin in both the U.S. and Europe under a dual-track strategy that addressed COVID-related restrictions on imports

“In a mere 18 months from our IPO, our laser focus on this program created a potentially pivotal study now open for enrollment, with patient dosing expected to commence at any time. With the addition of our recent Fast Track Designation for GBM, we believe we are poised to execute on our milestones ahead and bring a meaningful treatment to patients who suffer from this devastating and heretofore incurable disease,” Climaco added. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP